MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38α protein

Current Medicinal Chemistry

Volumn 12, Issue 25, 2005, Pages 2979-2994

  Lee, Matthew R ^a   Dominguez, Celia ^a  

^a AMGEN INC   (United States)

Author keywords

"DGF in"; "DGF out"; AMG 548; BIRB 796; IL 1 ; MAP kinase; p38 inhibitors; SCIO 469; TNF

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADENOSINE TRIPHOSPHATE; AMG 548; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DORAMAPIMOD; EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROGEN; INTERLEUKIN 1BETA; INTERLEUKIN 8; ISOPROTEIN; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PLACEBO; PROTEIN KINASE LCK; PROTEIN KINASE ZAP 70; PROTEIN SERINE THREONINE KINASE; SCIO 323; SCIO 469; STRESS ACTIVATED PROTEIN KINASE 1; SX 011; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702;

BLEEDING; CELL STIMULATION; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; GENE ACTIVATION; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; LIVER DYSFUNCTION; MONOCYTE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RNA TRANSLATION; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27944503331     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986705774462914     Document Type: Review

References (73)

1. Foster, M.; Halley, F.; Souness, J.E. Drug News Perspect. 2000, 13, 488-497.
2. Rutgeerts, P.; D'Haens, G.; Targan, S.; Vasiliauskas, E.; Hanauer, S.B.; Present, D.H.; Mayer, L.; Van Hogezand, R.A.; Braakman, T.; DeWoody, K.L.; Schaible, T.F.; Van Deventer, S.J.H. Gastroenterology 1999, 117, 761-769.
3. Arend, W.P.; Dayer, J.M. Arthritis Rheum. 1990, 33, 305-315.
4. Firestein, G.S.; Alvaro-Gracia, J.M.; Maki, R. J. Immunol. 1990, 144, 3347-3353.
5. Ulfgren, A.K.; Andersson, U.; Engstrom, M.; Klareskog, L.; Maini, R.N.; Taylor, P.C. Arthritis Rheum. 2000, 43, 2391-2396.
6. Ritchlin, C. Arthritis Res. 2000, 2, 356-360.
7. Lee, J.C.; Laydon, J.T.; McDonnell, P.C.; Gallagher, T.F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M.J.; Heys, J.R.; Landvatter, S.W.; Strickler, J.E.; McLaughlin, M.M.; Siemens, I.R.; Fisher, S.M.; Livi, G.P.; White, J.R.; Adams, J.L.; Young, P.R. Nature 1994, 372, 739-746.
8. Vertex Pharmaceutical Inc. Vertex moves to re-allocate resources from V-745 in p38 map kinase program to accelerate development of second generation drug candidates VX-702 and VX-850. Press release, September 2001.
9. IDdb drug reference 401259: Drug development update - keliximab, pexiganan, SB-209247, SB-218842, SB-240683, SB-242235, glaspomid, levcromakalim, MAGE-3 anticancer vaccine, HIV vaccine, hepatitis E vaccine, extra strength hepatitis B vaccine and malaria vaccine. Company Communication, 2001. 8, 2426
10. Regan, J. The identification of BIRB-796, an inhibitor of p38MAP kinase: Four pivotal discoveries. Drew Residential School on Medicinal Chemistry, Madison, NJ, 2004.
11. Zack, D.; Campagnuolo, G.S.; Middleton, S.; Koch, A.; Zhu, L.; Bolon, B.; Feige, U. 66th American College of Rheumatology Annual Scientific Meeting, Orlando, FL, 2003, 834.
12. Dominguez, C.; Liu, L.; Zhang, D.; Tamayo, N.; Powers, D.; Wong, M.; Feige, U.; Harris, R.; Wild, S.; Neervannan, S.; Syed, R.; Harvey, T. 228th American Chemical Society Meeting, Philadelphia, PA, 2004, MEDI 189.
13. Madwed, J. IBC Protein Kinase Conference, San Diego, CA, 2002.
14. Grob, P.M.; Madwed, J.B.; Pargellis, C.; Yong, C.L. Method for administering BIRB 796 BS. Patent WO03049742, published June 19, 2003. (Boehringer Ingelheim Pharmaceuticals, Inc).
15. Polmar, S.H.; Yong, C.L.; Wood, C.C.; Staehle, H.; Gupta, A. J. Allergy Clin. Immunol. 2002, 109 (Suppl. 1), S66.
16. Schreiner, G. IBC Protein Kinase Conference, San Diego, CA, 2002.
17. Mavunkel, B.J.; Chakravarty, S.; Perumattam, J.J.; Dugar, S.; Lu, Q.; Liang, X. Indole-type derivatives as inhibitors of p38 kinase. Patent WO0071535, published November 30, 2000. (Scios Inc.).
18. Goehring, R.R.; Luedtke, G.R.; Mavunkel, B.J.; Chakravarty, S.; Dugar, S.; Schreiner, G.F.; Liu, D.Y.; Lewicki, J.A. Inhibitors of p38α kinase. Patent WO0012074, published March 9, 2000. (Scios Inc.).
19. Cirillo, P.F.; Pargellis, C.; Regan, J. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors. Curr. Top. Med Chem. 2002, 2, 1021-1035.
20. Study of oral SCIO-469 in relapsed, refractory patients with multiple myeloma. Clinical Trials. gov, Bethesda, MD, 2005. http://www.clinicaltrials.gov/ct/show/NCT00087867?order=3.
21. Tong, M.D.; Daniels, D.O.; Montano, T.; Chang, S.; Desjardins, P. Clin. Pharm. Ther. 2004, 75, P3.
22. IDdb drug report: SCIO-323. Thomson Scientific Ltd., London, UK.
23. Salituro. F.; Bemis, G.; Cochran, J. Inhibitors of p38. Patent WO0017175, published March 30, 2000. (Vertex Pharmaceuticals, Inc.)
24. Salituro. F.; Bemis, G.; Evindar, G. Pyridine derivatives as inhibitors of p38. Patent WO0170695A1, published September 27, 2001. (Vertex Pharmaceuticals, Inc.)
25. Vertex Pharmaceutical Inc. Preliminary phase Iia data for VX-702 demonstrate tolerability and reduction in C-reactive protein in cardiovascular patients. Press release, October 18, 2004.
26. Manuscript submitted to EOTP.
27. Bellon, S.; Fitzgibbon, M. J.; Fox, T.; Hsiao H. M.; Wilson, K. P. Structure 1999, 7, 1057-1065.
28. Stein, B.; Yang, M. X.; Young, D. B.; Janknech, R.; Hunter, T.; Murray, B. W.; Barbosa, M. S. J. Biol. Chem. 1997, 272, 19509-19517.
29. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. Science 2002, 298, 1912-1934.
30. Dombroski, M.A.; Duplantier, A.J.; Laird, E.R.; Letavic, M.A.; Mcclure, K.F. Triazolopyridines As Anti-Inflammatory Agents. Patent published WO02072579A1 September 19, 2002. (Pfizer Products Inc.).
31. Bonjouklian, R.; De Diego Gomez, J.E.; De Dios, A.; Hamdouchi, C.H.; Li, T.; Lopez De Uralde Garmendia, B.; Vieth, M.; York, J.S.; Dally, R.D.; Del Prado Catalina, M.F.; Jaramillo, C.; Martin Cabrejas, L.M.; Montero Salgado, C.; Pleite, S.; Sanchez-Martinez, C.; Shepherd, T.A.; Wikel, J.H. Benzimidazoles And Benzothiazoles As Inhibitors Of Map Kinase. Patent WO04014900A1, published February 19, 2004. (Eli Lilly and Company).
32. Dombroski, M.A.; Letavic, M. A.; McClure, K. F.; Barberia, J. T.; Carty, T. J.; Cortina, S. R.; Csiki, C.; Dipesa, A. J.; Elliott, N. C.; Gabel, C. A.; Jordan, C. K.; Labasi, J, M.; Martin, W. H.; Peese, K. M.; Stock, I. A.; Svensson, L.; Sweeney, F. J.; Yu, C. H. Bioorg. Med. Chem. Lett. 2004, 14, 919-923.
33. Sawyer, J.S.; Teicher, B.A.; Yingling, J.M. Methods Of Inhibiting TGF Beta With Substituted Pyrazoles. Patent WO04026302A1, published April 1, 2004. (Eli Lilly and Company).
34. Huse, M.; Kuriyan, J. Cell 2002, 109, 275-282.
35. Dominguez, C.; Powers, D.A.; Tamayo, N. Curr. Opin. Drug Discov. Devel. 2005, 8, 421-430.
36. Kubo, A.; Imashiro, R.; Sakurai, H.; Miyoshi, H.; Ogasawara, A.; Hiramatsu, H. 4-Imidazolin-2-One Compounds. Patent WO03035638A1, published May 1, 2003. (Tanabe Seiyaku Co. Ltd.).
37. Clark, M.P.; Laufersweiler, M.J.; Djung, J.F.; Natchus, M.G.; De, B. 6,7-Dihydro-5h-Pyrazolo[1,2-A]Pyrazol-1-Ones Which Control Inflammatory Cytokines. Patent WO03024971A1, published Mar 27, 2003. (The Proctor & Gamble Company).
38. Colletti, S.L.; Frie, J.L.; Dixon, E.C.; Singh, S.B.; Choi, B.K.; Scapin, G.; Fitzgerald, C.E.; Kumar, S.; Nichols, E.A.; O'Keefe, S.J.; O'Neill, E.A.; Porter, G.; Samuel, K.; Schmatz, D.M.; Schwartz, C.D.; Shoop, W.L.; Thompson, C.M.; Thompson, J.E.; Wang, R.; Woods, A.; Zaller, D.M.; Doherty, J.B. J. Med. Chem. 2003, 46, 349-352.
39. Rupert, K.C.; Henry, J.R.; Dodd, J.H.; Wadsworth, S.A.; Cavender, D.E.; Olini, G.C.; Fahmy, B.; Siekierka, J.J. Biorg. Med. Chem. Lett. 2003, 13, 347-350.
40. Trejo, A.; Arzeno, H.; Browner, M.; Chanda, S.; Cheng, S.; Comer, D.D.; Dalrymple, S.A.; Dunten, P.; Lafargue, J.; Lovejoy, B.; Freire-Moar, J.; Lim,J.; Mcintosh, J.; Miller, J.; Papp, E.; Reuter, D.; Roberts, R.; Sanpablo, F.; Saunders, J.; Song, K.; Villasenor, A.; Warren, S.D.; Welch, M.; Weller, P.; Whiteley, P.E.; Zeng, L.; Goldstein, D.M. J. Med. Chem. 2003, 46, 4702-4713.
41. Adams, J.L.; Boehm, J.C.; Gallagher, T.F.; Kassis, S.; Webb, E.F.; Hall, R.; Sorenson, M.; Garigipati, R.; Griswold, D.E.; Lee, J.C. Biorg. Med. Chem. Lett. 2001, 11, 2867-2870.
42. Revesz, L; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Zimmerlin, A. G. Biorg. Med. Chem. Lett. 2000, 10, 1261-1264.
43. Revesz, L.; Blum, e.; Di Padova, F. E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Rucklin, G. Biorg. Med. Chem. Lett. 2004, 14, 3595-3599.
44. McIntyre, C.J.; Ponticello, G.S.; Liverton, N.J.; O'Keefe, S.J.; O'Neill, E.A.; Pang, M.; Schwartz, C.D.; Claremon, D.A. Biorg. Med. Chem. Lett. 2002, 12, 689-692.
45. Minami, N.; Sato, M.; Hasumi, K.; Yamamoto, N.; Keino, K.; Matsui, T.; Kanada, A.; Ohta, S.; Saito, T.; Sato, S.; Asagarasu, A.; Doi, S.; Kobayashi, M.; Sato, J.; Asano, H. Aminopyrazole Derivatives. Patent WO0039116A1, published July 6, 2000. (Teikoku Hormone Mfg. Co., Ltd.).
46. Bemis, G.W.; Salituro, F.G.; Duffy, J.P.; Cochran, J.E.; Harrington, E.M.; Murcko, M.A.; Wilson, K.P.; Su, M.; Galullo, V.P. Substituted Nitrogen Containing Heterocycles As Inhibitors Of P38 Protein Kinase. Patent WO9827098A1, published June 25, 1998. (Vertex Pharmaceuticals, Inc.).
47. Schlapbach, A.; Heng, R.; Di Padova, F. Biorg. Med. Chem. Lett. 2004, 14, 357-360.
48. Liu, L.; Stelmach, J.E.; Natarajan, S.R.; Chen, M.H.; Singh, S.B.; Schwartz, C.D.; Fitzgerald, C.E.; O'Keefe, S.J.; Zaller, D.M.; Schmatz, D.M.; Doherty, J.B. Biorg. Med. Chem. Lett. 2003, 13, 3979-3982.
49. Natarajan, S. R.; Wisnoski, D. D.; Singh, S. B.; Stelmach, J. E.; O'Neill, E. A.; Schwartz, C. D.; Thompson, C. M.; Fitzgerald, C. E.; O'Keefe, S. J.; Kumar, S.; Hop, C. E.; Zaller, D. M.; Schmatz, D. M.; Doherty, J. B. Biorg. Med. Chem. Lett. 2003, 13, 273-276.
50. Fitzgerald, C. E.; Patel, S. B.; Becker, J. W.; Cameron, P. M.; Zaller, D.; Pikounis, V. B.; O'Keefe, S. J.; Scapin, G. Nat. Struct. Biol. 2003, 10, 764-769.
51. Stelmach, J. E.; Liu, L.; Patel, S. B.; Pivnichny, J. V.; Scapin, G.; Singh, S.; Hop, C. E.; Wang, Z.; Strauss, J. R.; Cameron, P. M.; Nichols, E. A.; O'Keefe, S. J.; O'Neill, E. A.; Schmatz, D. M.; Schwartz, C. D.; Thompson, C. M.; Zaller, D. M.; Doherty, J. B. Biorg. Med. Chem. Lett. 2003, 13, 277-280.
52. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Luedtke, G. R.; Liang, X.; Lim, D.; Xu, Y. J.; Laney, M.; Liu, D. Y.; Schreiner, G. F.; Lewicki, J. A.; Dugar, S. Biorg. Med. Chem. Lett. 2003, 13, 3087-3090.
53. Mavunkel, B. J.; Chakravarty, S.; Perumattam, J. J.; Liu, D. Y.; Luedtke, G. R.; Lu, Q.; Dugar, S.; Laney, M.; Henson, M.; Xu, Y. J.; Almirez, R.; Scott, B.; Lewicki, J. A.; Moore, A.; Lee, S.; Brahn, E.; Protter, A.; Schreiner, G. Discovery & Biological Evaluation of p38a MAP Kinase Inhibitor SX-011. Poster presented on May 5-8, 2004, at ACSMC, in Moscow Russia.
54. Ottosen, E.R.; Sorensen, M.D.; Bjorkling, F.; Skak-Nielsen, T.; Fjording, M.S.; Aaes, H.; Binderup, L. J. Med. Chem. 2003, 46, 5651-5662.
55. Revesz, L.; Blum, E.; Di Padova, F.E.; Buhl, T.; Feifel, R.; Gram, H.; Hiestand, P.; Manning, U.; Rucklin, G. Biorg. Med. Chem. Lett. 2004, 14, 3601-3605.
56. Hubbard, S. R.; Wei, L.; Ellis, L.; Hendrickson, W. A. Nature, 1994, 372, 746-754.
57. Wilson, K. P.; Fitzgibbon, M. J.; Caron, P. N.; Griffith, J. P.; Chen, W. Y.; Mccaffrey, P. G.; Chambers, S. P.; Su, M. S. S. J. Biol. Chem. 1996, 271, 27696-27700.
58. Pargellis, C.; Tong, L.; Churchill, L.; Cirillo, P.F.; Gilmore, T.; Graham, A.G.; Grob, P.M.; Hickey, E.R.; Moss, N.; Pav, S.; Regan, J. Nat. Struct. Biol. 2002, 9, 268-272.
59. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. J. Med. Chem. 2002, 45, 2994-3008.
60. Dumas, J.; Sibley, R.; Riedl, B.; Monahan, M. K.; Lee, W.; Lowinger, T. B.; Redman, A. M.; Johnson, J. S.; Kingery-Wood, J.; Scott, W. J.; Smith, R. A.; Bobko, M.; Schoenleber, R.; Ranges, G. E.; Housley, T. J.; Bhargava, A.; Wilhelm, S. M.; Shrikhande, A. Biorg. Med. Chem. Lett. 2000, 10, 2047-2050.
61. Angell, R.M.; Aston, N.M.; Bamborough, P.; Bamford, M.J.; Cockerill, G.S.; Merrick, S.J.; Walker, A.L. 5′-Carbamoyl-1,1′-Biphenyl-4-Carboxamide Derivatives And Their Use As P38 Kinase Inhibitors. Patent WO03032980A1, published April 24, 2003. (Glaxo Group Limited).
62. Angell, R.M.; Baldwin, I.R.; Bamborough, P.; Deboeck, N.M.; Longstaff, T.; Swanson, S. Fused Heteroaryl Derivatives For Use As P38 Kinase Inhibitors In The Treatment Of I.A. Rheumatoid Arthristis. Patent WO04010995A1, published February 5, 2004. (Smithkline Beecham Corporation).
63. Hynes, J.; Wu, H.; Leftheris, K.; Liu, C.; Das, J.; Moquin, R.V. Thiazolyl-Based Compounds Useful As Kinase Inhibitors. Patent WO04071440, published August 26, 2004. (Bristol-Myers Squibb Company).
64. Leftheris, K.; Barrish, J.; Hynes, J.; Wrobleski, S.T. Methods Of Treating P38 Kinase-Associated Conditions And Pyrrolotriazine Compounds Useful As Kinase Inhibitors. Patent WO0240486, published May 23, 2002. (Bristol-Myers Squibb Company).
65. Ahmed, G.; Metzger, A.; Wrobleski, S.T.; Henderson, I.; Wen, J.; Diller, D.J. Leftheris, K. N-Heterocyclic Inhibitors Of TNF-Alpha Expression. Patent WO03002544, published January 9, 2003, (Bristol-Myers Squibb Company).
66. Moriarty, K.J.; Shimshock, Y.; Ahmed, G.; Wu, J.; Wen, J.; Li, W.; Erickson, S.D.; Letourneau, J.J.; Mcdonald, E.; Leftheris, K.; Wrobleski, S.T. Cytokine, Especially TNF-Alpha, Inhibitors. Patent WO0147897, published July 5, 2001. (Bristol-Myers Squibb Company).
67. Cuenda, A.; Rouse, J.; Doza, Y. N.; Meier, R.; Cohen, P.; Gallagher, T. F.; Young P. R.; Lee, J. C. FEBS Lett. 1995, 364, 229-233.
68. Fabian, M. A.; Biggs III, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lélias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. Nature Biotechnology 2005, 23, 329-336.
69. Cho, S. J.; Sun, Y. a program to FLexibly Align MolEcule. manuscript submitted to J Med. Chem.
70. Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham III, T. E.; Wang, J.; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Gohlke, H.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. AMBER Version 7, 2002, University of California, San Francisco.
71. Moss, N. An evaluation of the [Phe out] binding mode for kinase inhibitors. Presented at ACS ProSpectives Discovery and Selection of Successful Drug Candidates, Boston, MA, May 2005.
72. Wilson, K. P.; Mccaffrey, P. G.; Hsiao, K.; Pazhanisamy, S.; Galullo, V.; Bemis GW; Fitzgibbon, M. J.; Garon, P. R.; Murcko, M. A.; Su, M. S. S. Chem. Biol. 1997, 4, 423-431.
73. Wang, Z.L.; Canagarajah, B.J.; Boehm, J.C.; Kassisa, S.; Cobb, M.H.; Young, P.R.; Abdelmeguid, S.; Adams, J.L.; Goldsmith, E. J. Structure 1998, 6, 1117-1128.